Search

TG Therapeutics Inc

Fechado

SetorSaúde

64.4 0.36

Visão Geral

Variação de preço das ações

24h

Atual

Mín

63.94

Máximo

64.62

Indicadores-chave

By Trading Economics

Rendimento

48M

55M

Vendas

20M

260M

P/E

Médio do Setor

94.597

68.089

EPS

0.35

Margem de lucro

21.337

Funcionários

399

EBITDA

64M

86M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+18.43% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

525M

9.7B

Abertura anterior

64.04

Fecho anterior

64.4

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de nov. de 2026, 21:13 UTC

TG Therapeutics, Inc. shares are modestly lower in after-market trading, reflecting broader market declines influenced by the Federal Reserve's financial stability report.

12 de nov. de 2026, 23:06 UTC

TG Therapeutics, Inc. shares are modestly lower in after-market trading following fluctuations earlier in the session.

11 de nov. de 2026, 23:06 UTC

TG Therapeutics, Inc. is trading slightly lower in after-market hours after peaking earlier.

10 de nov. de 2026, 21:03 UTC

Social Media
News

TG Therapeutics stock advanced after Evercore ISI maintained its Outperform rating and J.P. Morgan raised its global revenue guidance to $1 billion.

9 de nov. de 2026, 23:06 UTC

Social Media

TG Therapeutics, Inc. is trading slightly higher in after-market hours following the completion of a $100 million share repurchase program, buying back 3.5 million shares.

6 de nov. de 2026, 22:51 UTC

TG Therapeutics, Inc. is trading modestly higher in after-market hours, reflecting broader market gains following strong U.S. labor market data for October.

5 de nov. de 2026, 23:03 UTC

TG Therapeutics, Inc. shares advanced modestly during after-market hours on Thursday, fluctuating from negative territory to a high nearing 1%.

4 de nov. de 2026, 23:26 UTC

TG Therapeutics, Inc. is roughly flat in after-market trading, slightly declining from an early high but remaining above its 20-day moving average.

3 de nov. de 2026, 22:51 UTC

TG Therapeutics, Inc. is advancing in after-market trading, moving higher alongside the broader market following a recovery from an initial dip after Tuesday's close.

2 de nov. de 2026, 23:51 UTC

TG Therapeutics, Inc. shares advanced in after-market trading, moving higher alongside the broader market, despite some volatility during the session.

31 de out. de 2026, 00:02 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, reaching its highest cumulative return of the day and significantly surpassing Friday's close.

30 de out. de 2026, 23:31 UTC

TG Therapeutics, Inc. shares traded modestly higher during after-market hours on Friday, continuing a trend of higher daily closes since the prior close.

29 de out. de 2026, 22:26 UTC

TG Therapeutics, Inc. is experiencing a notable decline in after-market trading, retracing from earlier gains and marking a significant drop since Thursday's close.

28 de out. de 2026, 23:06 UTC

Social Media

TG Therapeutics, Inc. shares are trading lower in after-market hours ahead of earnings on Monday, fluctuating between a loss of over two percent and a slight gain.

27 de out. de 2026, 20:51 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, recovering from earlier losses to reach a notable peak above its 20-day moving average.

26 de out. de 2026, 20:13 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, following three consecutive sessions of gains and an unusual lack of variation.

23 de out. de 2026, 20:03 UTC

Social Media
News

TG Therapeutics announced initial Phase 1 study results showing 89% of participants with progressive multiple sclerosis had stable or improved disability scores at Day 90.

22 de out. de 2026, 20:07 UTC

TG Therapeutics Inc shares fell slightly, retracing from an early peak and ending near the lower end of their one-month range.

21 de out. de 2026, 19:36 UTC

Social Media
News

TG Therapeutics presented new clinical data for BRIUMVI at the MSToronto2026 conference, showing 88% of patients free from disability progression after continuous treatment.

20 de out. de 2026, 22:36 UTC

Social Media

TG Therapeutics Inc is trading lower in after-market hours, having retraced from an earlier high and positioned near the lower end of its one-month trading range.

19 de out. de 2026, 20:07 UTC

Social Media

Shares of TG Therapeutics Inc are declining, finishing well below the 20-day moving average and near the lower end of the one-month range.

16 de out. de 2026, 19:53 UTC

Social Media

TG Therapeutics Inc shares are declining sharply, trading well below their 20-day moving average and near the lower end of their one-month range.

15 de out. de 2026, 20:07 UTC

TG Therapeutics Inc shares advanced, peaking in the late morning and settling near the day's high, remaining above its 20-day moving average.

14 de out. de 2026, 23:21 UTC

TG Therapeutics Inc shares declined in after-market trading, moving lower alongside the broader market amid significant declines in technology stocks and rising crude oil prices.

12 de out. de 2026, 19:56 UTC

Social Media
News

TG Therapeutics published a five-year study showing BRIUMVI has a lower risk of disability progression compared to ocrelizumab and ofatumumab in relapsing multiple sclerosis.

10 de out. de 2026, 00:01 UTC

TG Therapeutics Inc shares are trading modestly higher in after-market hours, continuing a trend of four consecutive sessions finishing higher.

9 de out. de 2026, 23:20 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, having fluctuated between a decline and a slight gain since Friday's close.

8 de out. de 2026, 19:15 UTC

News
Social Media
Event

TG Therapeutics schedules the 10th Joint ACTRIMS-ECTRIMS Meeting for October 21-23, 2026, to present initial clinical results of Azer-Cel and BRIUMVI data.

7 de out. de 2026, 20:01 UTC

TG Therapeutics Inc is trading higher, having previously peaked earlier in the session before pulling back, and remains below its 20-day moving average.

6 de out. de 2026, 20:00 UTC

TG Therapeutics Inc shares fell sharply, reaching an early high before declining significantly, remaining well below its 20-day moving average.

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

18.43% parte superior

Previsão para 12 meses

Média 76.4 USD  18.43%

Máximo 86 USD

Mínimo 71 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

6 ratings

5

Comprar

0

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat